Genetic sequence analysis of influenza viruses and illness severity in ill children previously vaccinated with live attenuated or inactivated influenza vaccine

Vaccine

Volumn 28, Issue 31, 2010, Pages 5128-5134

  Yang, Chin Fen ^a   Belshe, Robert B ^b   Kemble, George ^a   Song, Eyun ^a   Ye, Dan ^a   Liang, Brandon ^a   Yi, Tingting ^a   Ambrose, Christopher S ^a   Coelingh, Kathy ^a   Walker, Robert E ^a,c  

^a MEDIMMUNE   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Aeras Global TB Vaccine Foundation   (United States)

Author keywords

Hemagglutinin A1; Influenza; Live attenuated influenza vaccine

Indexed keywords

INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; VIRUS RNA;

ARTICLE; CHILD; DISEASE SEVERITY; GENE SEQUENCE; HUMAN; INCIDENCE; INFANT; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; VIRUS GENE; VIRUS STRAIN; CLASSIFICATION; COMPARATIVE STUDY; GENETICS; INFLUENZA, HUMAN; PHYLOGENY; PRESCHOOL CHILD; SEQUENCE ANALYSIS;

CHILD, PRESCHOOL; HUMANS; INCIDENCE; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; PHYLOGENY; RNA, VIRAL; SEQUENCE ANALYSIS, RNA; VACCINES, ATTENUATED; VACCINES, INACTIVATED;

EID: 77954758935     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.02.109     Document Type: Article

References (36)

1. Izurieta H.S., Thompson W.W., Kramarz P., Shay D.K., Davis R.L., DeStefano F., et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med 2000, 342(4):232-239.
2. Long C.E., Hall C.B., Cunningham C.K., Weiner L.B., Alger K.P., Gouveia M., et al. Influenza surveillance in community-dwelling elderly compared with children. Arch Fam Med 1997, 6(5):459-465.
3. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Bridges C.B., Cox N.J., et al. Influenza-associated hospitalizations in the United States. JAMA 2004, 292(11):1333-1340.
4. Neuzil K.M., Mellen B.G., Wright P.F., Mitchel E.F., Griffin M.R. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med 2000, 342(4):225-231.
5. Glezen W.P., Taber L.H., Frank A.L., Gruber W.C., Piedra P.A. Influenza virus infections in infants. Pediatr Infect Dis J 1997, 16(11):1065-1068.
6. Monto A.S., Sullivan K.M. Acute respiratory illness in the community. Frequency of illness and the agents involved. Epidemiol Infect 1993, 110(1):145-160.
7. Neuzil K.M., Hohlbein C., Zhu Y. Illness among schoolchildren during influenza season: effect on school absenteeism, parental absenteeism from work, and secondary illness in families. Arch Pediatr Adolesc Med 2002, 156(10):986-991.
8. Glezen W.P., Couch R.B. Interpandemic influenza in the Houston area, 1974-76. N Engl J Med 1978, 298(11):587-592.
9. Glezen W.P. Emerging infections: pandemic influenza. Epidemiol Rev 1996, 18(1):64-76.
10. Ashkenazi S., Vertruyen A., Aristegui J., Esposito S., McKeith D.D., Klemola T., et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 2006, 25(10):870-879.
11. Belshe R.B., Edwards K.M., Vesikari T., Black S.V., Walker R.E., Hultquist M., et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007, 356(7):685-696.
12. Fleming D.M., Crovari P., Wahn U., Klemola T., Schlesinger Y., Langussis A., et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2006, 25(10):860-869.
13. Belshe R.B., Gruber W.C., Mendelman P.M., Mehta H.B., Mahmood K., Reisinger K., et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 2000, 181(3):1133-1137.
14. Belshe R.B., Gruber W.C., Mendelman P.M., Cho I., Reisinger K., Block S.L., et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 2000, 136(2):168-175.
15. He X.S., Holmes T.H., Zhang C., Mahmood K., Kemble G.W., Lewis D.B., et al. Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol 2006, 80(23):11756-11766.
16. Forrest B.D., Pride M.W., Dunning A.J., Capeding M.R., Chotpitayasunondh T., Tam J.S., et al. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol 2008, 15(7):1042-1053.
17. Nichol K.L., Mendelman P.M., Mallon K.P., Jackson L.A., Gorse G.J., Belshe R.B., et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 1999, 282(2):137-144.
18. Piedra P.A., Gaglani M.J., Kozinetz C.A., Herschler G.B., Fewlass C., Harvey D., et al. Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children. Pediatrics 2007, 120(3):e553-e564.
19. Tam J.S., Capeding M.R., Lum L.C., Chotpitayasunondh T., Jiang Z., Huang L.M., et al. Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia. Pediatr Infect Dis J 2007, 26(7):619-628.
20. Hoft D.F., Worku S., Lottenbach K., Stanley J., Spencer C., Babusis E., et al. Live attenuated influenza vaccine (LAIV), but not trivalent inactivated vaccine (TIV), induces functional CD4+ CD8+ and γδ T cell responses in children relevant for pandemic influenza. The Twelfth Annual Conference on Vaccine Research 2009, [Abstract S14].
21. Belshe R.B., Ambrose C., Yi T. Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of age. Vaccine 2008, 26S:D10-16.
22. Wei Z., McEvoy M., Razinkov V., Polozova A., Li E., Casas-Finet J., et al. Biophysical characterization of influenza virus subpopulations using field flow fractionation and multiangle light scattering: correlation of particle counts, size distribution and infectivity. J Virol Methods 2007, 144(1-2):122-132.
23. Harper S.A., Fukuda K., Uyeki T.M., Cox N.J., Bridges C.B. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2004, 53(RR-6):1-40.
24. Kumar S., Tamura K., Nei M. MEGA3: integrated software for molecular evolutionary genetics analysis and sequence alignment. Brief Bioinform 2004, 5(2):150-163.
25. Guess H.A., Lydick E.G., Small R.D., Miller L.P. Epidemiologic programs for computers and calculators. Exact binomial confidence intervals for the relative risk in follow-up studies with sparsely stratified incidence density data. Am J Epidemiol 1987, 125(2):340-347.
26. Wang Q., Cheng F., Lu M., Tian X., Ma J. Crystal structure of unliganded influenza B virus hemagglutinin. J Virol 2008, 82(6):3011-3020.
27. Wang Q., Tian X., Chen X., Ma J. Structural basis for receptor specificity of influenza B virus hemagglutinin. Proc Natl Acad Sci USA 2007, 104(43):16874-16879.
28. Berton M.T., Naeve C.W., Webster R.G. Antigenic structure of the influenza B virus hemagglutinin: nucleotide sequence analysis of antigenic variants selected with monoclonal antibodies. J Virol 1984, 52(3):919-927.
29. WHO Collaborating Center for Surveillance, Epidemiology and Control of Influenza. Information for the vaccines and related biological products advisory committee, CBER, FDA. Available at: [Accessed January 7, 2010]. http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4207-index.htm.
30. Belshe R.B., Mendelman P.M., Treanor J., King J., Gruber W.C., Piedra P., et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med 1998, 338(20):1405-1412.
31. Holmes E.C., Ghedin E., Miller N., Taylor J., Bao Y., St George K., et al. Whole-genome analysis of human influenza A virus reveals multiple persistent lineages and reassortment among recent H3N2 viruses. PLoS Biol 2005, 3(9):e300.
32. WHO Collaborating Center for Surveillance, Epidemiology and Control of Influenza. Information for the vaccines and related biological products advisory committee, CBER, FDA. Available at: [Accessed January 7, 2010]. http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4087b1.htm.
33. World Health Organization (WHO) Recommended composition of influenza virus vaccines for use in the 2006 influenza season. Wkly Epidemiol Rec 2005, 80(40):342-347.
34. Nakagawa N., Nukuzuma S., Haratome S., Go S., Nakagawa T., Hayashi K. Emergence of an influenza B virus with antigenic change. J Clin Microbiol 2002, 40(8):3068-3070.
35. Rota P.A., Wallis T.R., Harmon M.W., Rota J.S., Kendal A.P., Nerome K. Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology 1990, 175(1):59-68.
36. Belshe R.B., Coelingh K., Ambrose C.S., Woo J.C., Wu X. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. Vaccine 2009, 10.1016/j.vaccine.2009.11.068.